Pipeline
Differentiated programs across multiple modalities — antibodies, TCR-CD3 T-cell engagers, and radioconjugates.
| Program | Target | Indication Focus | Modality | Stage |
|---|---|---|---|---|
| HP-001 | 暂未披露 | 实体瘤（与 PD-1i 联用） | 免疫检查点抗体 |
|
| HP-002 | PRAME | PRAME-positive solid tumors | 肿瘤细胞胞内抗原 |
|
| HP-002 (ext) | 暂未披露 | Solid tumors | Same platform |
|
| HP-004 | ALPP / ALPPL2 | Solid tumors (ovarian, endometrial, gastric, NSCLC) | ADC |
|
Discovery
→
Preclinical
→
IND-enabling
→
Phase I
→
Phase II
HP-001
临床前
Target: 暂未披露
Indication: 实体瘤（与 PD-1i 联用）
Modality: 免疫检查点抗体
HP-002
Preclinical
Target: PRAME
Indication: PRAME-positive solid tumors
Modality: 肿瘤细胞胞内抗原
HP-002 (ext)
Discovery
Target: 暂未披露
Indication: Solid tumors
Modality: Same platform
HP-004
Preclinical
Target: ALPP / ALPPL2
Indication: Solid tumors (ovarian, endometrial, gastric, NSCLC)
Modality: ADC